MindMed's recent financing has closed after being upsized all the way to CAD$34.5 million.
Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs Inc. Completion of Initial DMT Research Drug Batch and Exercise of Warrants
Entheon has secured a supply of DMT for delivery to its drug research center (CHDR) in the Netherlands.
Champignon Brands Appoints Christopher Hobbs as Interim Chief Financial Officer
Champignon Brands names an interim CFO after Stephen Brohman resigns.
Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms
Mydecine completes its first commercial harvest of 20 kilograms of psilocybin mushrooms.
Mind Cure Establishes Psychedelic Compound Research Program
Mind Cure Health will be focusing its psychedelic drug R&D on psilocybin, ketamine and ibogaine. The Company will be pursuing both pain-based and mental health applications for psychedelics.
Mind Cure Announces its Research Program with Psychedelic Compounds
Mind Cure's initial R&D focus will be on psilocybin, ketamine and ibogaine. Researching both pain and mental health applications for psychedelics.
Prominent Bitcoin Investor’s Next Monster Bet
One of Bitcoin’s most prominent investors is making a new monster bet.
CYBIN Signs Definitive Agreement to Acquire Adelia Therapeutics as Part of its Commitment to Strategic Growth
Cybin Corp acquires Adelia Therapeutics in an all-stock transaction valued at CAD$20.2 million.
Numinus Wellness Inc. Announces $10 Million Bought Deal Public Offering
Numinus announces a bought deal financing at CAD$0.68 cents.
Will ATAI’s IPO Help Or Hurt Compass Pathways?
ATAI Life Science's IPO in 2021 is expected to be another big industry catalyst. But one company that might NOT benefit is Compass Pathways.
Entheon Biomedical Announces Corporate Update Including Investment in Wonder Scientific
Entheon discusses its new strategic investment in Wonder Scientific.
BIG Psychedelics Financings Powering Future Investor Profits
Nearly half a billion dollars has recently flooded into the coffers of psychedelic drug companies. That's enough capital to power a lot of growth.
